Cargando…

MUM1 Expression versus Hans Algorithm to Predict Prognosis in Indonesian Diffuse Large B-Cell Lymphoma Patients Receiving R-CHOP

BACKGROUND: Treatment response in diffuse large B-cell lymphoma (DLBCL) is heterogenous. The Hans algorithm (using 30% cut-offs for CD10, BCL6, and MUM1 protein expression) has been the most favored method to categorize DLBCL into germinal center B-cell (GCB) and non-GCB subtypes in order to predict...

Descripción completa

Detalles Bibliográficos
Autores principales:	Irawan, Cosphiadi, Iskandar, Martha, Harahap, Agnes Stephanie, Rumende, Cleopas Martin, Ham, Maria Francisca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898019/ https://www.ncbi.nlm.nih.gov/pubmed/35256863 http://dx.doi.org/10.2147/CMAR.S345745

Ejemplares similares

The distinct clinical features and prognosis of the CD10(+)MUM1(+) and CD10(−)Bcl6(−)MUM1(−) diffuse large B-cell lymphoma
por: Lu, Ting-Xun, et al.
Publicado: (2016)

Risk of developing cognitive impairment on patients with chronic obstructive pulmonary disease: A systematic review
por: Simargi, Yopi, et al.
Publicado: (2022)

Clinicopathological Profile of Thyroid Carcinoma in Young Patients: An Indonesian Single-Center Study
por: Harahap, Agnes Stephanie, et al.
Publicado: (2022)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

Accuracy of serum-specific IgE test with microfluidic array enzyme-linked immunosorbent assay for diagnosing inhalant allergen sensitization in asthma and/or rhinitis allergy patients in Jakarta, Indonesia
por: Sinurat, Julfreser, et al.
Publicado: (2018)

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
por: Cho, Kyoung Min, et al.
Publicado: (2019)

Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)

The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
por: Rajabto, Wulyo, et al.
Publicado: (2022)

Risk factors for early invasive fungal disease in critically ill patients
por: Singh, Gurmeet, et al.
Publicado: (2016)

Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy
por: Guo, Jiaxun, et al.
Publicado: (2021)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era
por: Sofo-Hafizovic, Alma, et al.
Publicado: (2016)

Sciatic diffuse large B-cell lymphoma with treatment response to CHOP and radiotherapy
por: Shomal Zadeh, Firoozeh, et al.
Publicado: (2023)

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients
por: Huang, Ying, et al.
Publicado: (2012)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms
por: Wang, Liang, et al.
Publicado: (2021)

Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy
por: Pettengell, R., et al.
Publicado: (2008)

Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
por: Gutiérrez, Antonio, et al.
Publicado: (2015)

GM-CSF enhanced the effect of CHOP and R-CHOP on inhibiting diffuse large B-cell lymphoma progression via influencing the macrophage polarization
por: Zhang, Yu, et al.
Publicado: (2021)

Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis
por: Painschab, Matthew S, et al.
Publicado: (2021)

Undifferentiated Nasopharyngeal Carcinoma Presenting with Shoulder Mass
por: Irawan, Cosphiadi, et al.
Publicado: (2020)

Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements
por: Frauenfeld, Leonie, et al.
Publicado: (2022)

Mum I'll sleep on grave
Publicado: (2008)

The role of IL-6, ferritin, and coagulopathy in Covid-19 clinical progression
por: Harahap, Alvin Tagor, et al.
Publicado: (2023)

Gut microbiota profile in healthy Indonesians
por: Rahayu, Endang Sutriswati, et al.
Publicado: (2019)

R‐CHOP‐14 versus R‐CHOP‐14/CHASER for upfront autologous transplantation in diffuse large B‐cell lymphoma: JCOG0908 study
por: Kagami, Yoshitoyo, et al.
Publicado: (2020)

R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
por: Lee, Hong Ghi, et al.
Publicado: (2014)

Complications and outcomes in diffuse large B‐cell lymphoma with gastric lesions treated with R‐CHOP
por: Kadota, Tomohiro, et al.
Publicado: (2019)

Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
por: Choi, Soyeon, et al.
Publicado: (2022)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital
por: Harahap, Agnes Stephanie, et al.
Publicado: (2023)

Role of Pretreatment Hemoglobin-to-Platelet Ratio in Predicting Survival Outcome of Locally Advanced Nasopharyngeal Carcinoma Patients
por: Irawan, Cosphiadi, et al.
Publicado: (2021)

Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis
por: Hong, Junshik, et al.
Publicado: (2010)

Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience
por: Jeong, Jae-Uk, et al.
Publicado: (2017)

P1216: ZANUBRUTINIB PLUS R-CHOP(RI-CHOP) AS THE TREATMENT FOR DOUBLE EXPRESSION OF MYC/BCL2 IN PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA
por: Ren, K., et al.
Publicado: (2022)

PLP helps the mother centrosome stay mum
por: Short, Ben
Publicado: (2013)

R-CHOP versus CHOP in HIV-associated lymphoma: a meta-analysis of prospective studies
por: Echenique, Ignacio, et al.
Publicado: (2012)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
por: Tessoulin, Benoit, et al.
Publicado: (2023)

Obstructing Duodenal Diffuse Large B-cell Lymphoma with Peritoneal Lymphomatosis with Exceptional Response to R-CHOP
por: Zaarour, Mazen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ci3ht95qdgdjctnsoo54m0sc01